• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    1,068.94 -0.80 (-0.07%)
    Streaming Delayed Price Updated: 10:27 AM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 22,170
    Open 1,077.80
    Bid (Size) 1,069.53 (1)
    Ask (Size) 1,071.72 (4)
    Prev. Close 1,069.74
    Today's Range 1,062.92 - 1,077.80
    52wk Range 721.51 - 1,106.16
    Shares Outstanding 91,779,465
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    $100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
    Via Benzinga
    Peering Into Regeneron Pharmaceuticals's Recent Short Interest
    Via Benzinga

    Performance

    YTD
    +18.11%
    +18.11%
    1 Month
    +0.47%
    +0.47%
    3 Month
    +18.75%
    +18.75%
    6 Month
    +13.38%
    +13.38%
    1 Year
    +47.01%
    +47.01%

    More News

    Read More
    Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
    Via Benzinga
    3 Standout Stocks to Buy for the Next Bull Market
    Via InvestorPlace
    Stocks to Buy: 7 Founder-Led Companies Set to Outperform
    Via InvestorPlace
    Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
    Via Benzinga
    The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
    Via Benzinga
    If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
    Via Benzinga
    CPI Data Sparks Rally in Biotech Stocks
    Via MarketBeat
    Topics ETFs Economy
    Exposures Interest Rates
    Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
    Via Benzinga
    Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
    Via The Motley Fool
    The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
    Via InvestorPlace
    Looking Into Regeneron Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
    Via Talk Markets
    3 No-Brainer Stocks to Buy in July
    Via The Motley Fool
    3 Pharma Stocks Already Ushering in the Next Biotech Boom
    Via InvestorPlace
    The 3 Best Biotech Stocks to Buy in July 2024
    Via InvestorPlace
    What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
    Via Investor's Business Daily
    7 High Priced Stocks That Would Benefit From a Stock Split
    Via InvestorPlace
    Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
    Via Benzinga
    Exposures Product Safety
    Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    What's Going On With Regeneron Pharmaceuticals Stock On Friday?
    Via Benzinga
    Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
    Via Benzinga
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.